Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    19487376 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting The MetNET-2 Trial
Condition: Neuroendocrine Tumors
Intervention: Drug: Lanreotide and Metformin
2 Not yet recruiting The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
Condition: Resectable Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Metformin Hydrochloride 500Mg Tablet
3 Recruiting Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
Condition: Glioblastoma Multiforme
Intervention: Drug: Metformin
4 Recruiting Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer
Condition: Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Metformin;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.